Electron- and positron-emitting radiolanthanides for therapy: Aspects of dosimetry and production

Journal of Nuclear Medicine

Volumn 47, Issue 5, 2006, Pages 807-814

  Uusijärvi, Helena ^a   Bernhardt, Peter ^a   Rösch, Frank ^b   Maecke, Helmut R ^c   Forssell Aronsson, Eva ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Dosimetry; Production; Radiolanthanides; Radionuclide therapy

Indexed keywords

CERIUM; DYSPROSIUM; ERBIUM; EUROPIUM; GADOLINIUM; HOLMIUM; IODINE; LANTHANIDE; LANTHANUM; LUTETIUM; NEODYMIUM; PRASEODYMIUM; PROMETHIUM; SAMARIUM; TERBIUM; THULIUM; YTTERBIUM; YTTRIUM; RADIOISOTOPE;

ARTICLE; DOSIMETRY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG HALF LIFE; ISOTOPE LABELING; PHOTON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCINTISCANNING; TUMOR; TUMOR VOLUME; CHEMISTRY; ELECTRON; HUMAN; METHODOLOGY; POSITRON EMISSION TOMOGRAPHY; RADIOMETRY; TIME;

ELECTRONS; HOLMIUM; HUMANS; LANTHANOID SERIES ELEMENTS; LUTETIUM; POSITRON-EMISSION TOMOGRAPHY; PROMETHIUM; RADIOISOTOPES; RADIOMETRY; TERBIUM; THULIUM; TIME FACTORS; YTTRIUM RADIOISOTOPES;

EID: 33745555830     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Rösch F, Forssell-Aronsson E. Radio-lanthanides in nuclear medicine. In: Sigel H, ed. Metal Ions and Their Complexes in Medication. New York, NY: Marcel Dekker, Inc.; 2004:77-108.
2. 3-octreotate in an animal model. J Nucl Med. 2004;45:1542-1548.
3. 3]octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer. 2001;92:628-633.
4. 177Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. J Nucl Med. 2004;45:1224-1232.
5. 0]octreotide in patients. Eur J Nucl Med. 2001;28:1319-1325.
6. 3]octreotate. Eur J Nucl Med Mol Imaging. 2003;30:417-422.
7. 3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23:2754-2762.
8. 3]octreotate. J Clin Oncol. 2004;22:2724-2729.
9. 90Y-DOTATOC. J Nucl Med 2005;46:1310-1316.
10. Wessels BW, Rogus RD. Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies. Med Phys. 1984;11:638-645.
11. Bernhardt P, Benjegard SA, Kolby L, et al. Dosimetric comparison of radio-nuclides for therapy of somatostatin receptor-expressing tumors. Int J Radiat Oncol Biol Phys. 2001;51:514-524.
12. Bernhardt P, Forssell-Aronsson E, Jacobsson L, Skarnemark G. Low-energy electron emitters for targeted radiotherapy of small tumours. Acta Oncol. 2001;40:602-608.
13. Mäcke H, Good S. Radiometals (non-Tc, non-Re) and bifunctional labeling chemistry. In: Vèrtes A, Nagy S, Klencsár Z, Rösch F, eds. Handbook of Nuclear Chemistry, Volume 4. Dordrecht, The Netherlands: Kluwer Academic Publishers; 2003:279-314.
14. 68Ga. Eur J Nucl Med Mol Imaging. 2005;32:478-485.
15. Mirzadeh S, Mauser LF, Garland MA. Reactor-produced medical radionuclides. In: Vèrtes A, Nagy S, Klencsár Z, Rösch F, eds. Handbook of Nuclear Chemistry, Volume 4. Dordrecht, The Netherlands: Kluwer Academic Publishers; 2003:1-46.
16. Rösch F, Knapp F. Radionuclide generators. In: Vèrtes A, Nagy S, Klencsàr Z, Rösch F, eds. Handbook of Nuclear Chemistry, Volume 4. Dordrecht, The Netherlands: Kluwer Academic Publishers; 2003:81-118.
17. 140Nd. Acta Oncol. 2000;39:727-730.
18. 134La, an Auger electron and positron-emitting generator for radionuclide therapy. Phys Med Biol. 2002;47:615-629.
19. Berger MJ. Improved Point Kernel for Electrons and Beta-Ray Dosimetry. Washington DC: U.S. Atomic Energy Commission; 1973.
20. Brownell GL, Ellett WH, Reddy AR. Absorbed fractions for photon dosimetry. J Nucl Med. 1968;(suppl 1):27-39.
21. Ellett W, Humes R. Absorbed fractions for small volumes containing photonemitting radioactivity. J Nucl Med. 1972;13(suppl 5):26-32.
22. Browne E, Firestone RB. Table of Radioactive Isotopes. New York, NY: Wiley-Interscience Publication; 1986.
23. Chu SYF, Ekström LP, Firestone RB. WWW Table of Radioactive Isotopes. 1999. Available at: http://nucleardata.nuclear.lu.se/nucleardata/toi/. Accessed March 20, 2006.
24. 177Lu process. Appl Radiat Isot. 2000;53:421-425.
25. Cutler CS, Ehrhardt GJ, Tyler TT, Jurisson SS, Deutsch E. Current and potential therapeutic uses of lanthanide radioisotopes. Cancer Biother Radiopharm. 2000;15:531-545.
26. 153Sm for radionuclide therapy. Nucl Med Commun. 2002;23:83-89.
27. Neves M, Kling A, Lambrecht RM. Radionuclide production for therapeutic radiopharmaceuticals. Appl Radiat Isot. 2002;57:657-664.
28. Tse JW, Wiebe LI, Noujaim AA. High specific activity [samarium-153] EDTA for imaging of experimental tumor models. J Nucl Med. 1989;30:202-208.
29. 161Tb-DTPA-octreotide, a somatostatin analogue with potential for intraoperative scanning and radiotherapy. Eur J Nucl Med. 1995;22:608-616.
30. Hu F, Cutler CS, Hoffman T, Sieckman G, Volkert WA, Jurisson SS. Pm-149 DOTA bombesin analogs for potential radiotherapy: in vivo comparison with Sm-153 and Lu-177 labeled DO3A-amide-betaAla-BBN(7-14)NH(2). Nucl Med Biol. 2002;29:423-430.
31. Wahl RL, Kroll S, Zasadny KR. Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation. J Nucl Med. 1998;39(suppl):14S-20S.
32. Andersson P, Forssell-Aronsson E, Johanson V, et al. Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phe1-octreotide. J Nucl Med. 1996;37:2002-2006.
33. Bernhardt P, Ahlman H, Forssell-Aronsson E. Model of metastatic growth valuable for radionuclide therapy. Med Phys. 2003;30:3227-3232.
34. O'Donoghue JA. Implications of nonuniform tumor doses for radioimmunotherapy. J Nucl Med. 1999;40:1337-1341.
35. Bernhardt P, Ahlman H, Forssell-Aronsson E. Modelling of metastatic cure after radionuclide therapy: influence of tumor distribution, cross-irradiation, and variable activity concentration. Med Phys. 2004;31:2628-2635.